EMBO Member
Carola Ponzetto
EMBO 2000
Centro di Ricerca in Medicina Sperimentale (CERMS), Torino, Italy
Differentiation therapy of solid cancers (RMS)
We have shown that that miR-206, a microRNA responsible for downregulating the Met receptor during myogenesis, can push rhabdomyosarcoma (RMS) cells to resume differentiation, thus blocking tumor growth in xenograft models of RMS. Our current work is centered on the identification of other critical targets of miR-206, in the aim of developing a novel non-toxic approach to the treatment of RMS, a pediatric cancer often metastatic at diagnosis.
Keywords
Receptor tyrosine kinases / growth factor receptor signalling / RTKs in cancer / rhabdomyosarcoma / microRNAs